<code id='DBD6279FC3'></code><style id='DBD6279FC3'></style>
    • <acronym id='DBD6279FC3'></acronym>
      <center id='DBD6279FC3'><center id='DBD6279FC3'><tfoot id='DBD6279FC3'></tfoot></center><abbr id='DBD6279FC3'><dir id='DBD6279FC3'><tfoot id='DBD6279FC3'></tfoot><noframes id='DBD6279FC3'>

    • <optgroup id='DBD6279FC3'><strike id='DBD6279FC3'><sup id='DBD6279FC3'></sup></strike><code id='DBD6279FC3'></code></optgroup>
        1. <b id='DBD6279FC3'><label id='DBD6279FC3'><select id='DBD6279FC3'><dt id='DBD6279FC3'><span id='DBD6279FC3'></span></dt></select></label></b><u id='DBD6279FC3'></u>
          <i id='DBD6279FC3'><strike id='DBD6279FC3'><tt id='DBD6279FC3'><pre id='DBD6279FC3'></pre></tt></strike></i>

          entertainment

          entertainment

          author:knowledge    Page View:587

          Can the FDA be too flexible? How do you test a mechanical womb? And who decides what’s good enough for patients in need?

          We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Lizzy Lawrence joins us to explain the promise of artificial wombs and the debate over how to ethically develop them. We also discuss a momentous upcoming meeting in which FDA will consider the thorny case of a potential medicine for ALS whose supporting evidence has polarized patients and physicians.

          advertisement

          For more on what we cover, here’s the latest on artificial womb technology; here’s more on the ALS debate; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

          Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

          And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

          advertisement

          focus

          How to save PrEP access — and even expand it
          How to save PrEP access — and even expand it

          UndertheAffordableCareAct,healthinsurersarerequiredtocoverallcostsassociatedwithpreventivecare—inclu

          read more
          An inside look at PIPEs, biotech's buzzy new financing tool
          An inside look at PIPEs, biotech's buzzy new financing tool

          MollyFerguson/STATBiotechisawashinPIPEs.Thenumbersbehindtheseprivatelynegotiatedpurchasesofpublic-co

          read more
          DIEP, the 'gold standard' of breast reconstruction, is under threat
          DIEP, the 'gold standard' of breast reconstruction, is under threat

          AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

          read more

          Readout LOUD Podcast: Lilly's obesity drug, the power of radiation

          What’saradiopharmaceutical?WhatdoesitmeantobeZepbound?Andwho’stoblameforabiotechblow-up?Wecoverallth